“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Front Page » Vaccination » Future Vaccines » The Upcoming Trials for the First Malaria Vaccine
Future Vaccines
Text size:

The Upcoming Trials for the First Malaria Vaccine

African girl drinking water

“Malaria may be the best possible disease to illustrate that factors other than vaccination have been responsible for the dramatic improvement in global health over the last century.”— Kate Raines, The Vaccine Reaction

The World Health Organization (WHO) announced on Apr. 24, 2017 that it will conduct field trials in Ghana, Kenya, and Malawi next year on the world’s first malaria vaccine. The vaccine, known as RTS,S (Mosquirix), was developed by GlaxoSmithKline (GSK) of the United Kingdom.1 It is an injectable vaccine that reportedly offers partial protection against malaria in young children. The principle aim of the RTS,S vaccine is to protect children against the deadliest form of malaria caused by Plasmodium falciparum protozoan parasites which is transmitted by the female Anopheles mosquito and is most prevalent in Africa.2 3 4

According to the U.S. Centers for Disease Control and Prevention (CDC): “Infections caused by P. falciparum are the most likely to progress to severe, potentially fatal forms with central nervous system involvement (cerebral malaria), acute renal failure, severe anemia, or acute respiratory distress syndrome.”5

During 2009-2014, the RTS,S vaccine underwent a Phase III efficacy and safety trial involving 15,459 babies five to 17 months old in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania.1 3 The trial was coordinated by GSK, the PATH Malaria Vaccine Initiative (supported by the Bill & Melinda Gates Foundation), and a network of 11 research facilities in the seven African nations where the trial was conducted.1 3  The RTS,S vaccine was approved by the European Medicines Agency (EMA) on July 23, 2015.6 

The WHO field trials for RTS,S will aim to see if the Phase III trial can be “replicated in real-life.”1 

Specifically, the pilot program will assess the feasibility of delivering the required four doses of RTS,S, the vaccine’s potential role in reducing childhood deaths, and its safety in the context of routine use.1 

Work on a malaria vaccine is proceeding despite the fact that both the mortality and morbidity of the disease have been dramatically declining. “The number of new malaria cases fell by 21 percent between 2010 and 2015, and malaria mortality decreased by 29 percent overall and by 31 percent in Africa, where the vast majority of malarial cases occur,” noted Kate Raines in a recent article “Malaria Burden Worldwide Has Dropped Without Vaccines” in The Vaccine Reaction.7  She added: “For the period between 2000 and 2012, it was estimated that the number of deaths from malaria had fallen by 51 percent, resulting in an estimated 3.3 million lives saved, almost all of them children under age five.”7

Raines further explained: “Malaria may be the best possible disease to illustrate that factors other than vaccination have been responsible for the dramatic improvement in global health over the last century”7—which begs the broader question, “Do we even need a malaria vaccine?” As Raines pointed out in the opening paragraph:

It is a common position taken by vaccination proponents that vaccines deserve all the credit for the worldwide decrease in incidence and mortality from communicable diseases since the early 1900s. Last month, vaccines were credited with saving nearly a half million lives since 1963, in the U.S. alone. This popular stance glosses over such contributing factors as management of sewage disposal and the importance of hygienic practices, clean water, and food safety.7

Is this the standard historical pattern when it comes to vaccines, that major factors other than vaccines are responsible for the decline in the incidence and/or mortality of a disease, and, then, when a vaccine comes along late in the process, it is ultimately credited with having conquered the disease? This may ultimately be what will happen with the malaria vaccine. Will history erroneously get re-written, yet again, by the vaccine industry and public health officials anxious to point to mass vaccination programs as solely responsible for making the world safe from disease?


1 World Health Organization. Ghana, Kenya and Malawi to take part in WHO malaria vaccine pilot programme. Press Release Apr. 24, 2017.
2 Christensen J. First malaria vaccine to be widely tested in Africa next year. CNN Apr. 26, 2017.
3 Malaria Vaccine Initiative. Ghana, Kenya, and Malawi to take part in WHO malaria vaccine pilot programme. MalariaVaccine.org
4 Scientists Against Malaria. Plasmodium falciparum. ScientistsAgainstMalaria.net.
5 Centers for Disease Control and Prevention. DPDx—Laboratory Identification of Parasitic Diseases of Public Health Concern/Malaria. CDC.gov.
6 Fox M. Malaria Vaccine Mosquirix Approved by European Regulators. NBC News July 24, 2015.
7 Raines K. Malaria Burden Worldwide Has Dropped Without Vaccines. The Vaccine Reaction Apr. 14, 2017.

4 Responses to The Upcoming Trials for the First Malaria Vaccine

  1. Devon Reply

    May 3, 2017 at 10:36 am

    I just recently read this study… This malaria vaccine concerns me.

  2. ThinkingGrl Reply

    May 1, 2017 at 2:12 pm

    I need to search around for the original articles I read, but there’s information out there with regards to exposure to certain viruses being associated with reduced cancer rates. I linked to two articles showing that viruses are now being used to treat cancers. You may also want to look up disease nemesis theory.


  3. ThinkingGrl Reply

    April 28, 2017 at 8:35 am

    Sadly, I anticipate and uptick of other “mystery diseases” in these countries as the trials proceed. And we will never hear about the direct negative repercussions of this vaccine experiment. We almost never do. I also wonder about how this will impact the number of cases of sickle-cell anemia, as exposure to malaria is correlated with protection against sickle-cell anemia. Of course, down the line when it’s lucrative, we may see a genetically-engineered malaria virus turn up as the “miracle cure” for sickle-cell anemia in much the same way that polio virus is being used for brain cancer and measles virus is being used for other cancers…

    • Natalie Reply

      May 1, 2017 at 12:03 pm

      Hi Thinking Girl-

      I agree with your above statements.

      I was curious though what your last sentence meant ” much the same that polio…” etc etc
      Can you point me to information about what you mean here because I’m not familiar with what you are saying and it’s important to me to find out.

      Thank you

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>